McMurray JJ, Adamopoulos S, Anker SD, et al.-ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2012, 33, 1787-1847.
van Riet EE, Hoes AW, Limburg A, et al.-Prevalence of unrecognized heart failure in older persons with shortness of breath on exertion. Eur J Heart Fail, 2014, 16, 772-777.
Maggioni AP, Dahlstrom U, Filippatos G, et al.-EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail, 2013, 15, 808-817.
Gheorghiade M, De Luca L, Fonarow GC, et al.-Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol, 2005, 96, 11G-17G.
Ponikowski P, Voors AA, Anker SD, et al.-2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2016, 37, 2129-2200.
Swedberg K, Komajda M, Bohm M, et al.-Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet, 2010, 376, 875-885.
McMurray JJ, Packer M, Desai AS, et al.-Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail, 2014, 16, 817-825.
Abraham WT, Stevenson LW, Bourge RC, et al.-Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet, 2016, 387, 453-461.
van Deursen VM, Urso R, Laroche C, et al.-Comorbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail, 2014, 16, 103-111.
Ancion A, Lancellotti P, Pierard LA.-Insuffisance cardiaque et diabète. Rev Med Liege, 2005, 60, 536-540.
Zinman B, Wanner C, Lachin JM, et al.-Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015, 373, 2117-2128.
Scheen AJ.-EMPA-REG OUTCOME. L'empagliflozine réduit la mortalité chez le patient diabétique de type 2 à haut risque cardiovasculaire. Rev Med Liege, 2015, 70, 583-589.
Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al.-Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency dagger. Eur Heart J, 2015, 36, 657-668.
Cohn JN, Pfeffer MA, Rouleau J, et al.-Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail, 2003, 5, 659-667.
Vahanian A, Alfieri O, Andreotti F et al. The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).-Guidelines on the management of valvular heart disease (version 2012). Eur Heart J, 2012, 33, 2451-2496.
Filippatos G, Farmakis D, Parissis J, et al.-Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Med, 2015, 13, 35.
